Literature DB >> 24024871

The evolving history of influenza viruses and influenza vaccines.

Claude Hannoun1.   

Abstract

The isolation of influenza virus 80 years ago in 1933 very quickly led to the development of the first generation of live-attenuated vaccines. The first inactivated influenza vaccine was monovalent (influenza A). In 1942, a bivalent vaccine was produced after the discovery of influenza B. It was later discovered that influenza viruses mutated leading to antigenic changes. Since 1973, the WHO has issued annual recommendations for the composition of the influenza vaccine based on results from surveillance systems that identify currently circulating strains. In 1978, the first trivalent vaccine included two influenza A strains and one influenza B strain. Currently, there are two influenza B lineages circulating; in the latest WHO recommendations, it is suggested that a second B strain could be added to give a quadrivalent vaccine. The history of influenza vaccine and the associated technology shows how the vaccine has evolved to match the evolution of influenza viruses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24024871     DOI: 10.1586/14760584.2013.824709

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  76 in total

1.  The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.

Authors:  Jeremy C Jones; Bindumadhav M Marathe; Peter Vogel; Rodolfo Gasser; Isabel Najera; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).

Authors:  Luzhao Feng; Peng Yang; Tao Zhang; Juan Yang; Chuanxi Fu; Ying Qin; Yi Zhang; Chunna Ma; Zhaoqiu Liu; Quanyi Wang; Genming Zhao; Hongjie Yu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence.

Authors:  Ilaria Loperto; Andrea Simonetti; Antonio Nardone; Maria Triassi
Journal:  Hum Vaccin Immunother       Date:  2019-03-25       Impact factor: 3.452

4.  Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis.

Authors:  Tiffany W Y Ng; Benjamin J Cowling; Hui Zhi Gao; Mark G Thompson
Journal:  J Infect Dis       Date:  2019-04-19       Impact factor: 5.226

5.  [The universal influenza vaccination in children with Vaxigrip Tetra® in Italy: an evaluation of Health Technology Assessment].

Authors:  Sara Boccalini; Angela Bechini; Maddalena Innocenti; Gino Sartor; Federico Manzi; Paolo Bonanni; Donatella Panatto; Piero Luigi Lai; Francesca Zangrillo; Emanuela Rizzitelli; Mariasilvia Iovine; Daniela Amicizia; Chiara Bini; Andrea Marcellusi; Francesco Saverio Mennini; Alessandro Rinaldi; Francesca Trippi; Anna Maria Ferriero; Giovanni Checcucci Lisi
Journal:  J Prev Med Hyg       Date:  2018-05-30

6.  Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.

Authors:  Peter H Goff; Tomoko Hayashi; Luis Martínez-Gil; Maripat Corr; Brian Crain; Shiyin Yao; Howard B Cottam; Michael Chan; Irene Ramos; Dirk Eggink; Mitra Heshmati; Florian Krammer; Karen Messer; Minya Pu; Ana Fernandez-Sesma; Peter Palese; Dennis A Carson
Journal:  J Virol       Date:  2015-01-07       Impact factor: 5.103

7.  Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.

Authors:  Peter H Goff; Tomoko Hayashi; Wenqian He; Shiyin Yao; Howard B Cottam; Gene S Tan; Brian Crain; Florian Krammer; Karen Messer; Minya Pu; Dennis A Carson; Peter Palese; Maripat Corr
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

Review 8.  Influenza vaccines: challenges and solutions.

Authors:  Katherine Houser; Kanta Subbarao
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

9.  Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine.

Authors:  Guangyu Zhao; Yu Miao; Yan Guo; Hongjie Qiu; Shihui Sun; Zhihua Kou; Hong Yu; Junfeng Li; Yue Chen; Shibo Jiang; Lanying Du; Yusen Zhou
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus.

Authors:  Bin Zhou; Victoria A Meliopoulos; Wei Wang; Xudong Lin; Karla M Stucker; Rebecca A Halpin; Timothy B Stockwell; Stacey Schultz-Cherry; David E Wentworth
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.